Results-BP levels were linearly associated with incidence and mortality of CVD in men and women. According to the PAF estimation, the elimination of normal to severe hypertension would prevent 64% of stroke incidence in men and 50% in women; 67% of stroke mortality in men and 29% in women; and 38% of total CVD mortality in men and 36% in women. The PAF estimate for total stroke incidence was the highest for mild hypertension, and the smaller for moderate to severe hypertension in both sexes.
INTRODUCTION
Cardiovascular disease (CVD) remains a major public health burden in Japan (28% of deaths), 1 although mortality from stroke and coronary heart disease (CHD) has declined since the 1960s. 2 This decline may be attributable to the steady decline in the prevalence of hypertension, which in turn is probably due to nationwide hypertension control and lifestyle changes (e.g. lowering sodium intake) in Japan. 1 Hypertension is an established major risk factor for onset of CVD and as well as a prognostic factor [3] [4] [5] [6] [7] and it can readily be detected. 8 In fact, a recent study has suggested that primary prevention of hypertension could reduce CVD deaths four times more than could secondary prevention. 9 Identifying the population attributable fraction (PAF) associated with hypertension can offer significant insights into primary and secondary prevention of CVD. However, although there have been many reports on the PAF for CVD associated with hypertension from Western countries 7, 10, 11 , there have been far fewer from Asian countries. 12 Because prevalence of risk factors varies for different populations, a highly potent factor in one country could be less important in another where it is less common. Previous epidemiological studies have confirmed that hypertension is associated with higher relative risks for stroke and heart failure than for CHD. 9, 13 In Japan, where stroke is more common than CHD, elevated blood pressure (BP) may have a greater impact on CVD morbidity and mortality than other risk factors (i.e. hyperlipidemia and cigarette smoking). Yet, few studies have examined the PAFs associated with BP categories used in clinical practice on CVD and all-cause mortality 12 and CVD incidence. We therefore investigated the estimated PAFs and hazard ratios (HR) associated with BP levels on stroke and CHD incidence and mortality from CVD occurrence and mortality in a large-scale Japanese cohort study.
MATERIALS AND METHODS

Study Cohort
The first cohort of the Japan Public Health Center-based Prospective Study (JPHC Study) was initiated in 1990 (Cohort-I) the second in 1993 (Cohort-II) in 11 public health center areas throughout the country. 14 Two public health center areas (Tokyo and Osaka) were excluded from the present study because CVD incidence data were not available. The study population of the present study was defined as all residents (n =116,896) aged 40-59 years for
Cohort-I and 40-69 years for Cohort-II at baseline. Of these residents, 220 were excluded because of non-Japanese nationality (n=51), late reports of emigration occurring before the start of the follow-up period (n=166), and incorrect birth date (n=3). As a result, 116,676
residents remained eligible for the study. We informed the detail of the study to all study subjects. The protocol of the study was approved by the institutional review board of the National Cancer Center, Tokyo, Japan. A baseline self-administered questionnaire on various lifestyles was given to the residents in 1990, 1993 and 1994, and the 95,374 who responded were included in the study cohort. The overall response rate was 82%.
Baseline Questionnaire Survey and Health Examination
The questionnaire covered personal and family medical history, psychosocial factors such as perceived stress, household structure, as well as occupation, behavioral patterns and lifestyle factors such as smoking and alcohol habits, dietary habits, and physical activity. 
Confirmation of CHD and Stroke Incidence
A total of 64 hospitals were registered in the sampling area of the study cohort. All were major hospitals capable of treating patients with acute CHD and stroke. Physicians blinded to the patents' lifestyle data reviewed the medical records at each hospital. Acute CHD and stroke events were included in the study if they occurred after the date of return of the baseline questionnaire and before January 1, 2004.
The details of the surveillance for CHD were described previously. 16 
Confirmation of CHD and Stroke Mortality
All During the follow-up period, 2,254 of the study subjects died, 1,370 moved out of the study areas, and 79 were lost to follow-up.
Statistical analysis
Person-years for the follow-up period were counted from the date of the return of the baseline survey until one of the endpoints described hereafter. For the analysis of CHD or stroke incidence, person-years were censored at the date of disease diagnosis, the date of emigration from the study area, the date of death, or the end of the study period (December 31, 2003), whichever came first. For the analysis of deaths, person-years were censored at the date of emigration from the study area, the date of death, or the end of the study period, whichever came first. For persons who were lost to follow-up, the last confirmed date of their presence in the study area was used as the censoring date.
Analysis of covariance and chi-square tests were used to compare sex-specific age-adjusted mean values and percentages for CVD risk factors. For this study, outcomes were defined as newly occurring CHD and stroke incidence or deaths during the study period.
HRs and their 95% confidence intervals (95% CI) were calculated after adjustment for age and other potential risk factors by means of Cox proportional hazards models. The risk factors included age (years), public health center areas, smoking status (never, former, current), ethanol intake (non-and ex-drinkers, less than weekly, <150g/wk, 150-299g/wk, 300-449g/wk, or ≥450g/wk), body mass index (BMI, kg/m 2 in quintiles), antihypertensive medication use (yes or no), history of diabetes (yes or no), and serum total cholesterol levels (<4.14, 4.14-4.64, 4.65-5.16, 5.17-5.68, 5.69-6.20 and ≥6.21 mmol/L). We also calculated PAF to examine the contribution of the BP and its components to the risk of CVD, using multivariable HRs of statistical significance and the proportion of cases in each BP category. 19 PAF was estimated as pd × (HR−1)/HR, where pd is the proportion of cases falling into the category and the HR is the HR for the category relative to optimal BP.
We tested the assumption of proportional hazards by using both the time-dependent covariate method and the linear correlation test and found no violation of proportionality. The SAS statistical package Version 9.1 (SAS Institute Inc., Cary, NC) was used for all analyses. BP levels in relation to CVD risk factors were examined separately for men and women (Table 1) . Subjects were categorized into six levels of BP: optimal (23%), normal (22%), high normal (21%), mild (25%), moderate (7%), or severe hypertension (2%). Both men and women with optimal BP were younger than other subjects, more likely to be current smokers, and to have lower BMI, lower serum total cholesterol levels, lower antihypertensive medication use, lower history of diabetes and lower ethanol intake.
RESULTS
During
The HRs and PAF for stroke, stroke subtypes (IPH, SAH, ischemic stroke), and CHD are presented in Table 2 . For men, there were linear associations between BP levels and the incidence of total stroke, IPH and ischemic stroke and CHD. Similar linear relationships were observed for total stroke, IPH and ischemic stroke, and all endpoints in women except CHD incidence. There was no significant linear association between BP and risk of SAH in either men or women. Figure 1 also showed PAF, which represented the proportion of new stroke events in the entire cohort that would be prevented if normal to severe hypertension were eliminated. The elimination of normal to severe hypertension would prevent 64% of new stroke events in men: 6.1% from normal BP, 12.2% from high normal BP, 29.0% from mild hypertension, 11.5% from moderate hypertension, and 5.2% from severe hypertension, and 50% in women: 6.6%, 11.8%, 16.6%, 9.9% and 4.9%, respectively. The PAF estimate for total stroke incidence was the highest for mild hypertension, and was equal to or greater than that for moderate to severe hypertension in both men and women. Further, the PAF estimate was similar for high normal and moderate hypertension in both sexes. Table 3 shows the HRs and PAF estimates of mortality from stroke, CHD, cancer, CVD, other causes and all causes by BP category. We found linear relationships between BP levels and mortality from stroke and total CVD in both men and women and from all causes in men. Moderate and severe hypertension was significantly associated with increased risk of mortality from CHD and other causes in men, and severe hypertension with mortality from other causes in women. There was no significant association between BP and cancer mortality in either sex. According to the PAF estimation, the elimination of normal to severe hypertension would prevent 67% of stroke mortality in men and 29% in women, and 38% of total CVD mortality in men and 36% in women. The PAF estimate for total CVD mortality was the highest for mild hypertension, and was equal to or greater than that for moderate to severe hypertension.
For analysis of the PAF estimates of incidence and mortality from total CVD, further stratification by age group (40-64 and 65-69 years) was examined (data not shown). The PAF estimate for total CVD incidence was the highest for mild hypertension in both younger and older subjects. The PAF estimate for total CVD mortality was the highest for mild hypertension in younger subjects, even though no excess PAF estimate was found in older subjects.
We also examined whether the PAF estimates for any of the outcomes for non-antihypertensive medication users were different from the estimates for total subjects.
There were no differences between the PAF estimates for untreated subjects and total subjects (data not shown). For instance, normal, high normal, mild, moderate and severe categories accounted for 36% overall of total CVD mortality. The PAF estimate for total CVD mortality was the highest for mild hypertension (15%), and slightly larger than that for moderate to severe hypertension (13%).
DISCUSSION
In this large prospective analysis of a Japanese population, we found, after adjustment for cardiovascular risk factors, a linear relationship between BP and risks of stroke, IPH, ischemic stroke in both men and women and CHD in only men. Similarly, statistically significant linear relationships were detected between BP and risk of mortality from stroke, CVD and all causes for both men and women. The overall PAF of total stroke incidence from normal to severe hypertension (compared to optimal BP) was 64% in men and 50% in women. The overall PAF of CVD incidence and mortality from mild hypertension was equal to or greater than that from moderate to severe hypertension.
Hypertension has been shown to produce a strong predisposition to all of the major atherosclerotic CVD events. 7, 13 Further, clinical trials have documented striking reductions in stroke incidence as a result of antihypertensive medication therapy. 20, 21 Other preventive strategies such as antiplatelet therapy, lipid lowering, and smoking cessation have not been
shown to reduce the risk of stroke to the same degree. [22] [23] [24] [25] In addition, the potential benefits of hypertension control for reducing CVD may be greater than those of any other prevention strategies. For instance, the PAF of stroke incidence from smoking was 17% in men and 5%
in women 26 and that of CHD incidence from smoking was 46% in men and 9% in women, 27 whereas the PAF of stroke incidence from elevated BP was 64% in men and 50% in women and that of CHD incidence from elevated blood pressure was 41% in men and 33% in women in the present study.
Antihypertensive medication treatment is usually initiated for patients with moderate and severe hypertension. However, it should be realized that, whereas HRs of stroke and CHD are greater for moderate and severe hypertension, mild hypertension includes the vast majority of hypertensive individuals. In fact, the PAF estimates for stroke and CHD are higher for mild hypertension because it is so common. A prevention of events in the population is suboptimal if mild hypertension is inadequately controlled. A previous study reported that the elimination of normal (systolic pressure 120-129 mmHg and diastolic pressure 80-84 mmHg) and high normal BP (systolic pressure 130-139 mmHg or diastolic pressure 85-89 mmHg) would prevent 14% and 16% respectively of either incident ischemic stroke or CHD. 11 Our data similarly showed that the PAF estimates for the normal and high normal BP groups for incidence stroke or CHD to be 6% and 11%, respectively.
There are several limitations to our study. First, the proportion of subjects with data for both systolic and diastolic BP at baseline was only 30%, although the study subjects were selected from the general population. A previous report documented that non-participants had an unhealthier lifestyle than respondents, and were less likely to have undergone BP measurement in the health examination. 28 Thus, the prevalence of hypertension could be underestimated, but as a previous report suggested, 29 it is still uncertain whether HRs of CVD associated with hypertension was overestimated, underestimated or not. An exact effect of potential selection bias on PAFs is uncertain, but it is unlikely to change an overall picture of the findings. Second, since the study was not designed to analyze the effect of transitions, we
were not able to assess changes in BP as a predictor of CVD outcomes. The strength of the relationship between BP and CVD outcomes may thus have been underestimated. Third, although the present study is a large-scale nationwide representative sample of the general population, we excluded subjects from Tokyo and Osaka (first and second largest cities in Japan) due to incomplete event registration. Thus, it is uncertain whether our results are generalizable to metropolitan areas of Japan. Fourth, it was possible that we have had missed some of end points in the present study. Within the sampling areas of the JPHC study, a total of 78 hospitals formed the register of events. All were major hospitals with the capability of treating patients with acute CHD, stroke or cancer events. In the JPHC study, 97% of registered strokes and 92% of registered MIs were treated at these 78 hospitals and a few missing reports from hospitals or cases treated at outside of registered hospitals. 30 Furthermore, the JPHC Study involved local public health centers to systematically obtain hospital records and death certificates, which may have enhanced the accuracy of the JPHC stroke and MI registry. Finally, the numbers of events in some subsets such as women with CHD and men with SAH were small although the overall population was large. For that reason, conclusions related to these endpoints may have been limited.
The strengths of our study are its prospective design and large sample size, yielding robust statistical power for detecting the effects of BP stratified by gender.
To summarize, we found that BP was linearly associated with incidence and mortality from CVD. The overall effect of the normal, high normal, and mild hypertension categories for occurrence of stroke events was greater than that of the moderate and severe hypertension categories for both men and women. Our findings highlight the importance of control of low-to-moderate degrees of hypertension for primary prevention.
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